Alternative dosage schedules with HPV virus-like particle vaccines

Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule

(2014) Mathieu Boxus et al.   VACCINE

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

(2013) M. Safaeian et al.   Cancer Prevention Research

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

(2013) Simon R. M. Dobson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses

(2013) Mirte Scherpenisse et al.   PLoS One

Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months

(2013) Eduardo Lazcano-Ponce et al.   VACCINE

HPV—Beyond Cervical Cancer (Online Resource Center)

(2012) Kenneth A. Alexander et al.   AMERICAN JOURNAL OF MEDICINE

Germinal center selection and the development of memory B and plasma cells

(2012) Mark J. Shlomchik et al.   IMMUNOLOGICAL REVIEWS

Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination

(2012) Kinga K. Smolen et al.   VACCINE

Global Burden of Human Papillomavirus and Related Diseases

(2012) David Forman et al.   VACCINE

Human Papillomavirus Vaccines – Immune Responses

(2012) Margaret Stanley et al.   VACCINE

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

(2012) Cecilia M. Roteli-Martins et al.   Human Vaccines & Immunotherapeutics

Worldwide burden of cervical cancer in 2008

(2011) M. Arbyn et al.   ANNALS OF ONCOLOGY

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

(2011) Pierre Van Damme et al.   BMC INFECTIOUS DISEASES

Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old

(2011) Richard J. Hillman et al.   Clinical and Vaccine Immunology

Hepatitis B and the Need for a Booster Dose

(2011) E. Leuridan et al.   CLINICAL INFECTIOUS DISEASES

Switched memory B cells maintain specific memory independently of serum antibodies: The hepatitis B example

(2011) M. Manuela Rosado et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

(2011) Tino F. Schwarz et al.   Human vaccines & immunotherapeutics

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in Vietnam

(2011) Kathleen M. Neuzil   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

(2011) Ali Rowhani-Rahbar et al.   JOURNAL OF CLINICAL VIROLOGY

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

(2011) Aimée R. Kreimer et al.   JNCI-Journal of the National Cancer Institute

A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection

(2011) S. Longet et al.   JOURNAL OF VIROLOGY

Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study

(2011) Anna R Giuliano et al.   LANCET

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

(2011) Anna R. Giuliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia

(2011) Joel M. Palefsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years

(2011) Susanna Esposito et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Adolescent and young adult HPV vaccination in Australia: Achievements and challenges

(2011) Suzanne M. Garland et al.   PREVENTIVE MEDICINE

In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection

(2010) Patricia M. Day et al.   Cell Host & Microbe

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Randomized Trial of an Alternate Human Papillomavirus Vaccine Administration Schedule in College-Aged Women

(2010) Richard K. Zimmerman et al.   JOURNAL OF WOMENS HEALTH

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

(2010) Joseph G. Dauner et al.   VACCINE

Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

(2010) Hans-Ulrich Bernard et al.   VIROLOGY

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

(2009) S. K. Kjaer et al.   Cancer Prevention Research

Human B cell memory

(2009) Antonio Lanzavecchia et al.   CURRENT OPINION IN IMMUNOLOGY

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

(2009) Ali Rowhani-Rahbar et al.   VACCINE

Hepatitis B vaccines: WHO position paper—Recommendations

(2009)   VACCINE

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

(2009) Mark Schiffman et al.   Infectious Agents and Cancer

The Human Papillomavirus Infection in Men Study: Human Papillomavirus Prevalence and Type Distribution among Men Residing in Brazil, Mexico, and the United States

(2008) A. R. Giuliano et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

(2008) Elmar A. Joura et al.   VACCINE